Sprouty proteins: modified modulators, matchmakers or missing links?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Sprouty proteins are involved in organogenesis, particularly during the branching of endothelial tubes, and existing evidence suggests that Sprouty's point of action lies downstream of receptor signaling to inhibit the activation of the central Ras/Erk pathway. How Sprouty proteins accomplish their inhibitory action and whether they interact with other signaling pathways are significant questions. Sprouty proteins are devoid of any recognizable protein interaction domain, and clues as to how they function have been mainly derived from screening for interacting partners. Conserved across all the Sprouty proteins are three sequences: a Cbl-tyrosine kinase-binding (TKB) binding motif centered on an obligatorily phosphorylated tyrosine (Y55 in Sprouty2), a serine-rich motif (SRM) and a cysteine-rich domain (CRD). With the exception of a handful of proteins that bind to the N-terminus, most of the binding to Sprouty occurs via the CRD, predominantly by serine/threonine kinases that target sites within the SRM on Sprouty. Some of the resultant increase in phosphorylation is opposed by activated protein phosphatase 2A that binds to the N-terminal Cbl-TKB binding motif. Significantly, two ubiquitin E3 ligases also bind to the N-terminus of Sprouty: c-Cbl binds with high affinity to the TKB binding motif and SIAH2 binds constitutively to a different site; both proteins are able to direct the ubiquitination of Sprouty proteins and its destruction. The collective evidence points to Sprouty proteins as being substantially covalently-modified to control its location, stability, association, and destruction. With such stringent control of the Sproutys, the main question is what key proteins does this facilitator bring together?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Mechanisms of specificity in protein phosphorylation
Ubersax, J. A., & Ferrell Jr, J. E. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2203 · Cited by 1,451
Mapk signal specificity: The right place at the right time
Murphy, L. O., & Blenis, J. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.03.009 · Cited by 707
Sprouty, an intracellular inhibitor of Ras signaling
Casci, T., Vinós, J., & Freeman, M. (1999) · Cell · doi:10.1016/s0092-8674(00)80576-0 · Cited by 467 · cited 2×
“The CRD was also shown to influence the function of SPRY by localizing them to the cell membrane, both in Drosophila and in vertebrates (Casci et al .”
BackgroundThe Cbl interactome and its functions
Schmidt, M. H. H., & Dikic, I. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1762 · Cited by 395 · cited 1×
“SPRY could then make functional use of Cbl’s wide range of associate proteins as opposed to its ubiquitin E3 ligase ability (Schmidt & Dikic 2005, Thien & Langdon 2005).”
BackgroundAraki, T., Nawa, H., & Neel, B. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306461200 · Cited by 231 · cited 1×
“The activation of the Ras/ERK pathway downstream of a number of RTKs has been demonstrated to require the phosphatase activity of SHP2 (Araki et al .”
Background
Cited by
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Negative feedback regulation of the ERK1/2 MAPK pathway
Lake, D., Corrêa, S. A. L., & Müller, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2297-8 · Cited by 565
Raf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
Identification of New Genetic Risk Variants for Type 2 Diabetes
Shu, X. O., Long, J., Cai, Q., Qi, L., Xiang, Y.-B., Cho, Y. S., Tai, E. S., Li, X., Lin, X., Chow, W.-H., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001127 · Cited by 216
Next-generation sequencing identifies rare variants associated with Noonan syndrome
Chen, P.-C., Yin, J., Yu, H.-W., Yuan, T., Fernandez, M., Yung, C. K., Trinh, Q. M., Peltekova, V. D., Reid, J. G., Tworog-Dube, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324128111 · Cited by 186
“SPRY1 is a negative regulator of the RAS-ERK pathway, which reportedly binds to SHP2 (encoded by PTPN11) and RAF1 through its cysteine-rich domain (CRD) and inhibits ERK activation via an as yet unclear mechanism (35).”
Background
Metadata
- Authors
- Guy, G. R., Jackson, R. A., Yusoff, P., & Chow, S. Y.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2009-05-07
- Volume
- 203
- Issue
- 2
- Pages
- 191-202
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2109243577
- Cited by
- 129
- References
- 6
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.